- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:59 | AZ's ATR inhibitor ceralasertib flunks lung cancer test | ||
| 11:59 | Nine more companies sign pricing deals with Trump | ||
| 10:59 | BioMarin ends year with $4.8bn play for Amicus | ||
| Fr | US BIOSECURE Act passed by Congress | ||
| Do | CEPI steps in to fund Moderna's pandemic flu jab | ||
| Do | Ambros' $125m for pain disorder drug, and other financings | ||
| Do | J&J's subcutaneous Rybrevant cleared by FDA | ||
| Do | As year-end nears, pharma groups plump up their pipelines | ||
| Do | Lilly points to long-lasting weight loss with orforglipron | ||
| Do | Datroway filed for TNBC in EU after data delay | ||
| Do | Takeda plans filings for Sotyktu rival on new psoriasis data | ||
| Do | MSD claims two national priority vouchers; report | ||
| Do | As year-end nears, pharma groups boost their pipelines | ||
| Mi | Padcev/Keytruda scores again in early bladder cancer | ||
| Mi | DBV gets peanut allergy therapy programme back on track | ||
| Mi | LIB takes aim at cholesterol market with new PCSK9 option | ||
| Mi | UK, US approve GSK's twice-yearly asthma drug | ||
| Mi | CDC signs off on advice ending universal hepatitis B jabs | ||
| Di | Allergy Tx plots grass pollen jab launch after German okay | ||
| Di | Chai raises $130m for AI drug discovery platform | ||
| Di | Prof Jonathan Benger named as NICE's new CEO | ||
| Di | Enhertu moves into frontline breast cancer treatment | ||
| Di | J&J claims FDA's latest national priority voucher | ||
| 15.12. | Kyverna rises on stiff person syndrome data | ||
| 15.12. | J&J's run of talc lawsuit setbacks continues |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .